
Opinion|Videos|January 27, 2025
Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data
Author(s)Rebecca A. Shatsky, MD, Casey Degen, MD
Panelists discuss the factors influencing the choice between abemaciclib and ribociclib for adjuvant CDK4/6 inhibitor therapy, including patient characteristics and safety profiles, and explore strategies for toxicity management, maintaining dose intensity, and addressing adherence or toxicity challenges in real-world clinical practice.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What specific patient characteristics influence your choice between abemaciclib and ribociclib?
- In which scenarios would you preferentially choose abemaciclib over ribociclib? Ribociclib over abemaciclib?
- Could you discuss your approach to toxicity management with adjuvant CDK4/6 inhibitors?
- How do the different safety profiles of abemaciclib and ribociclib impact your patient selection? How do you weigh clinical considerations and comorbidities in your selection considerations?
- What strategies have you found most effective for maintaining dose intensity while managing adverse effects?
- How has real-world experience with adjuvant CDK4/6 inhibitors matched up with clinical trial data?
- What have been your key learnings about patient selection and management?
- How do you handle patients who struggle with adherence or toxicity in the first few months?
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


